Pfizer hikes 2025 profit outlook on cost cuts, strong quarterly results

Pfizer raised its full-year adjusted profit forecast due to cost cuts and strong business performance, beating Q2 revenue estimates driven by Covid products and other drugs.

The new profit guidance is $2.90 to $3.10 per share, up from $2.80 to $3.00, while maintaining its 2025 revenue outlook of $61 billion to $64 billion.

The company plans to record a $1.35 billion one-time charge linked to a cancer drug licensing deal, CNBC has reported.

Pfizer is also navigating potential impacts from U.S. tariffs and drug price pressure under the Trump administration, with ongoing talks to address drug affordability and competitiveness.

read more: https://www.cnbc.com/2025/08/05/pfizer-pfe-q2-2025-earnings-report.html

👍 Like this video if you're following how Big Pharma is navigating profits, policy shifts, and public health demands.
💬 Should drug companies face tighter price controls, or do profits fuel innovation? Share your take below.

🔗 Share this video to inform others about the financial and political pressures shaping the future of healthcare.

💰 Want to support the channel? Hit the YouTube Thanks button—your contribution helps us deliver high-quality, fact-based coverage of major health and business stories.

👉 Don’t forget to subscribe for more updates on pharma earnings, healthcare policy, and global drug markets.
Thanks for watching and supporting the channel.

Links for B.C.

Visit My Website
https://bcbegley.com

Follow Me On Facebook
https://www.facebook.com/B.C.Begley

Subscribe To My Patreon
https://www.patreon.com/bcbegley

Watch Me On YouTube
https://www.youtube.com/channel/UCGoUf-QQTlTN-BIh3ERCE9A

Follow Me On Twitter
https://twitter.com/BC_News1

Watch Me On Rumble
https://rumble.com/c/c-280191

Follow Me On Gab
https://gab.com/BC_Begley

Follow Me On Truth Social
https://truthsocial.com/@BC_Begley

Follow Me On BlueSky
https://bsky.app/profile/bcbegley.bsky.social

Watch Me On TikTok
https://www.tiktok.com/@bcbegley

#PfizerEarnings #PharmaUpdate #DrugPricingDebate